Compare Expedia Group Inc (EXPE) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs IDEXX Laboratories, Inc. — how do they compare? Expedia Group Inc trades at $273.12 (market cap $32.42B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Expedia Group Inc pays a 0.71% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| EXPE | IDXX | |
|---|---|---|
Market Cap | $32.42B | $40.43B |
Volume | 1,940,671 | 692,164 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $766.68 |
52-Week Low | $188.51 | $504.70 |
Typical Hold Time | 47 Days | 46 Days |
Enterprise Value | $30.98B | $41.32B |
Dividend Yield | 0.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $274.22, up 5.93% over the past 24 hours, reflecting strong momentum after three consecutive quarterly earnings beats. The stock shows a bullish technical signal with key resistance at $275 and support at $264. Fundamentally, the company reported $14.73B in 2025 revenue with a net income margin of 12.97%, while recent news highlights AI-driven competitive pressures and strategic partnerships.
The outlook for EXPE is cautiously optimistic, with a consensus price target of $335.06 implying 22% upside. Key opportunities include robust travel demand and improving profitability, but risks involve AI disruption from Meta's Muse agent and heightened competition. Analyst sentiment is mixed, with 47% buy ratings versus 50% hold, signaling balanced but uncertain near-term prospects.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
